# RaDaR

Source: https://onco.cc/drugs/radar-mrd/  
OnCo record `radar-mrd` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NeoGenomics' personalised blood test for tiny amounts of leftover cancer, tracking up to 48 mutations from the patient's own tumour.

## Summary

RaDaR was developed by Inivata (Cambridge, UK), acquired by NeoGenomics in 2021, and received FDA Breakthrough Device designation in 2021 for detecting residual disease and recurrence. Tracking dozens of variants at once lets it reach very low tumour fractions (parts per hundred thousand in validation studies) and it has been used in head and neck, breast and lung cancer cohorts, including the TRACERx-associated work in lung cancer. It is offered as a laboratory-developed test and competes with Signatera, Guardant Reveal and Oncodetect in a market that Medicare coverage decisions largely shape.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-09-10
- Tags: test
- Brand: RaDaR
- Modality: Tumour-informed ctDNA minimal residual disease test (up to 48 variants)
- Mechanism: Whole-exome sequencing of the tumour selects up to 48 patient-specific variants, which are tracked in plasma by deep amplicon sequencing with error suppression.

## Notes

- What a result means: as with other MRD tests, detection of tumour DNA in blood predicts relapse months before scans; how to act on it is still being defined in trials.

## Sources

- NeoGenomics: RaDaR (page moved; nearest live section): https://neogenomics.com/test-menu/

## Connected records

- drugs: [Guardant Reveal](https://onco.cc/drugs/guardant-reveal/), [Signatera](https://onco.cc/drugs/signatera/)
- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- companies: [NeoGenomics](https://onco.cc/companies/neogenomics/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/), [Diagnostics roadmap: stains → gene panels → blood tests that decide treatment](https://onco.cc/roadmaps/diagnostics-roadmap/)
- biomarkers: [ctDNA MRD positivity (molecular residual disease after curative treatment)](https://onco.cc/biomarkers/ctdna-mrd-positive/)

---
JSON: https://onco.cc/api/v1/entities/radar-mrd.json